No Data
No Data
Synaptogenix | 10-Q: Q2 2024 Earnings Report
Express News | Synaptogenix Announces New Collaboration With Lsu Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix Analyst Ratings
Maxim Group Upgrades Synaptogenix(SNPX.US) to Buy Rating, Announces Target Price $14
Express News | Synaptogenix Inc : Maxim Group Raises to Buy From Hold
Express News | Synaptogenix Announces FDA Authorization Of Its Investigational New Drug Application For Bryostatin-1 Trial In Multiple Sclerosis
No Data